Skip to main content

Advertisement

SpringerLink
Log in

Pfizer explores rare disease path

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

An Erratum to this article was published on 13 October 2010

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 22 September 2010

    In the version of this article initially published, it was reported that GlaxoSmithKline’s (GSK) EpiNova was one of several “biotech-like ideas” that “have been known to fizzle in pharma hands”; in fact, EpiNova has not “fizzled” but is in its second year of operation as a discovery performance unit of GSK focusing on epigenetic approaches to autoimmune disease. The error has been corrected in the HTML and PDF versions of the article.

Author information

Authors and Affiliations

  1. Ann Arbor, Michigan

    Catherine Shaffer

Authors
  1. Catherine Shaffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shaffer, C. Pfizer explores rare disease path. Nat Biotechnol 28, 881–882 (2010). https://doi.org/10.1038/nbt0910-881

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0910-881

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation